Company Overview
About Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
Business Model & Competitive Advantage
Prime editing is "find and replace" for genetic code: unlike CRISPR-Cas9 (which cuts DNA and relies on error-prone repair mechanisms), Prime editing makes precise targeted changes using a reverse transcriptase that writes new genetic sequences at the target site. This precision enables correction of point mutations — the genetic basis of thousands of rare diseases — without the unintended insertions and deletions that CRISPR cutting produces.
Competitive Landscape 2025–2026
The Phase 1 CGD (Chronic Granulomatous Disease) data presented by Prime Medicine represents the first human clinical validation of Prime editing: rapid restoration of NADPH oxidase function after a single ex vivo infusion in CGD patients demonstrates the technology works in human cells and achieves meaningful therapeutic correction. This data de-risks all of Prime's subsequent programs targeting rare genetic liver and blood diseases.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Prime Medicine is an established challenger with significant market presence and competitive offerings in BioTech.
Growth Stage
Prime Medicine has achieved $191M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Prime Medicine with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Prime Medicine? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Prime Medicine Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Prime Medicine vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →